The Patent Finder
CS

Cell Signaling Technology, Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

38 patents currently held

1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Jan 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
25
Ending by 2030
Jan 2027
Next term end
19
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 21, 2027
    The maintenance fee for Production of motif-specific and context-independent antibodies using peptide libraries as antigens (US 9,085,609) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
  • 1 fee due Mar 15, 2027
    The maintenance fee for Shower Plate and Substrate Processing Apparatus (US 9,136,097) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
  • 1 fee due Jul 7, 2027
    The maintenance fee for Translocation and Mutant Ros Kinase in Human Non-Small Cell Lung Carcinoma (US 10,526,661) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
  • 2 fees due Aug 2 to 4, 2027 · next Aug 2
  • 1 fee due Sep 3, 2027
    The maintenance fee for Multi Component Detection (US 10,577,640) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
  • 1 fee due Nov 3, 2027
    The maintenance fee for Translocation and Mutant Ros Kinase in Human Non-Small Cell Lung Carcinoma (US 9,328,349) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 18, 2026

What they patent

The 5 largest of its 19 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
PatentTitleStatusExpiresConfidence
US 11,099,188Ros Kinase in Lung Cancer
In force
 · Medium confidence
In forceMedium confidence
US 11,761,005Translocation and Mutant Ros Kinase in Human Non-Small Cell Lung Carcinoma
In force
 · High confidence
In forceHigh confidence
US 8,168,383Gene Defects and Mutant Alk Kinase in Human Solid Tumors
In force
 · High confidence
In forceHigh confidence
US 8,288,102Gene Defects and Mutant Alk Kinase in Human Solid Tumors
In force
 · High confidence
In forceHigh confidence
US 8,377,642Gene Defects and Mutant Alk Kinase in Human Solid Tumors
In force
 · High confidence
In forceHigh confidence
US 9,523,130Methods of Treating Non-Small Cell Lung Carcinoma (NSCLC)
In force
 · Medium confidence
In forceMedium confidence
US 9,988,688Compositions for Detecting Mutant Anaplastic Lymphoma Kinase in Lung Cancer
In force
 · High confidence
In forceHigh confidence
US 10,870,892Compositions for Detecting Mutant Anaplastic Lymphoma Kinase in Lung Cancer
In force
 · High confidence
In forceHigh confidence
US 10,955,416Compositions for Detecting Mutant Anaplastic Lymphoma Kinase in Human Lung Cancer
In force
 · Medium confidence
In forceMedium confidence
US 11,505,833Compositions for Detecting Mutant Anaplastic Lymphoma Kinase in Lung Cancer
In force
 · High confidence
In forceHigh confidence
10 of 38 patents shown.
Pro members see all 38.
Pro members: see all 38 patents
Also on record, not counted in the 38: 1 patent in force now held by others · 16 patents ended · 1 application pending · 69 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited